Nectar Lifesciences working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

—	—	186.68×	209.75×	211.77×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—	—	79.05×	71.33×	86.97×
—	—	114.43×	112.09×	100.36×
—	—	151.30×	168.99×	198.38×
0.02×	0.00×	7.74×	5.42×	4.48×
0.00×	0.00×	0.79×	0.77×	0.67×
1.19×	1.19×	−1.49×	44.99×	−5.53×
5.74×	5.74×	−6.40×	1.47×	2.48×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NECLIFE₹10.33

Nectar Lifesciences Limited

· Pharma & Health

₹ CrorePeersAAREYDRUGS NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹201 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	211.77	209.75	186.68	—	—
Receivable Days (DSO)	86.97	71.33	79.05	—	—
Payable Days (DPO)	100.36	112.09	114.43	—	—
Cash Conversion Cycle (days)	198.38	168.99	151.30	—	—
Working Capital Turnover	4.48	5.42	7.74	0.00	0.02
Asset Turnover	0.67	0.77	0.79	0.00	0.00
Cash Conversion (CFO/Net Income)	-5.53	44.99	-1.49	1.19	1.19
CFO/EBITDA	2.48	1.47	-6.40	5.74	5.74

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.